Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AbbVie not to seek accelerated approval for Rova-T after weak phase 2 SCLC trial data
The company said that it had consulted with the US Food and Drug Administration (FDA) and took the decision not to pursue the accelerated approval for the lung
The company said that it had consulted with the US Food and Drug Administration (FDA) and took the decision not to pursue the accelerated approval for the lung
Ilumya selectively adheres to the p19 subunit of IL-23 and suppresses its interaction with the IL-23 receptor to inhibit release of pro-inflammatory cytokines and chemokines. It will be
RB ended discussions with Pfizer regarding its proposal, which was for part of the business only. Financial Times reported that GlaxoSmithKline (GSK) is now leading the race for Pfizer's
The partnership will focus on developing three proteins, including tau, TDP-43 and an undisclosed target, implicated in the pathogenesis of various neurodegenerative diseases. Celgene will be provided with
Adcetris is an antibody-drug conjugate (ADC) that allows the antibody to direct the drug to a target on lymphoma cells known as CD30, which is considered to be
In a Nature Microbiology paper, the researchers reported that more than a quarter of the non-antibiotics restrict the growth of at least one species in the microbiome, which
HTX-011, which is a combination of local anesthetic bupivacaine and anti-inflammatory meloxicam, had produced statistically significant reductions in both pain intensity and need for opioids through 72 hours post-surgery.
As per the agreement terms, Lundbeck will pay an upfront amount of around DKK750m (€100m). The company is further required to pay up to DKK6bn (€805m) to Prexton in development,
The study showed that ALXN1210 achieved non-inferiority to Soliris (eculizumab) in complement inhibitor treatment-naïve patients with PNH based on the co-primary endpoints of transfusion avoidance and normalization of
Akcea, which is an affiliate of Ionis, is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with serious rare diseases. Inotersen is